These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35502766)

  • 21. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
    [No Abstract]   [Full Text] [Related]  

  • 22. Prognostic value of changes in serum carcinoembryonic antigen levels for preoperative chemoradiotherapy response in locally advanced rectal cancer.
    Cheong C; Shin JS; Suh KW
    World J Gastroenterol; 2020 Nov; 26(44):7022-7035. PubMed ID: 33311947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer with serum biomarkers.
    Clarke TL; White DA; Osborne ME; Shaw AM; Smart NJ; Daniels IR
    Ann R Coll Surg Engl; 2017 May; 99(5):373-377. PubMed ID: 28462648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer.
    Seierstad T; Hole KH; Grøholt KK; Dueland S; Ree AH; Flatmark K; Redalen KR
    Br J Radiol; 2015 Jul; 88(1051):20150097. PubMed ID: 25899892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predicting Pathological Complete Regression with Haematological Markers During Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.
    Lee JH; Song C; Kang SB; Lee HS; Lee KW; Kim JS
    Anticancer Res; 2018 Dec; 38(12):6905-6910. PubMed ID: 30504408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased Abundances of CD16
    Idel C; Polasky C; Ribbat-Idel J; Loyal K; Perner S; Rades D; Bruchhage KL; Pries R
    Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy.
    Huang TC; Liang CW; Li YI; Guo JC; Lin CC; Chen YJ; Cheng AL; Hsu CH
    J Cancer Res Clin Oncol; 2022 Jul; 148(7):1803-1811. PubMed ID: 34432128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor-Infiltrating PD-1+ Immune Cell Density is Associated with Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer.
    Kitagawa Y; Akiyoshi T; Yamamoto N; Mukai T; Hiyoshi Y; Yamaguchi T; Nagasaki T; Fukunaga Y; Hirota T; Noda T; Kawachi H
    Clin Colorectal Cancer; 2022 Mar; 21(1):e1-e11. PubMed ID: 35123891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy.
    Tsuchiya T; Someya M; Takada Y; Hasegawa T; Kitagawa M; Fukushima Y; Gocho T; Hori M; Nakata K; Hirohashi Y; Torigoe T; Saito T; Sakata KI
    Strahlenther Onkol; 2020 Aug; 196(8):725-735. PubMed ID: 31953603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.
    Lim SH; Hong M; Ahn S; Choi YL; Kim KM; Oh D; Ahn YC; Jung SH; Ahn MJ; Park K; Zo JI; Shim YM; Sun JM
    Eur J Cancer; 2016 Jan; 52():1-9. PubMed ID: 26623522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High Expression of VSTM2L Induced Resistance to Chemoradiotherapy in Rectal Cancer through Downstream IL-4 Signaling.
    Liu H; Zhang Z; Zhen P; Zhou M
    J Immunol Res; 2021; 2021():6657012. PubMed ID: 33506057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A combination of stromal PD-L1 and tumoral nuclear β-catenin expression as an indicator of colorectal carcinoma progression and resistance to chemoradiotherapy in locally advanced rectal carcinoma.
    Takahashi H; Watanabe H; Hashimura M; Matsumoto T; Yokoi A; Nakagawa M; Ishibashi Y; Ito T; Ohhigata K; Saegusa M
    J Pathol Clin Res; 2022 Sep; 8(5):458-469. PubMed ID: 35762092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer.
    Tsukada Y; Bando H; Inamori K; Wakabayashi M; Togashi Y; Koyama S; Kotani D; Yuki S; Komatsu Y; Homma S; Taketomi A; Uemura M; Kato T; Fukui M; Nakamura N; Kojima M; Kawachi H; Kirsch R; Yoshida T; Sato A; Nishikawa H; Ito M; Yoshino T
    Br J Cancer; 2024 Jul; 131(2):283-289. PubMed ID: 38834744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Could we use PD-1 and PD-L1 expression on lymphocytes and monocytes as predictive markers for prognosis of acute biliary pancreatitis?
    Idiz UO; Aru B; Kaya C; Peker KD; Tatar C; Guler M; Tunay A; Demirel GY; Gurol AO
    Immunol Lett; 2024 Feb; 265():37-43. PubMed ID: 38199503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognostic effect of neoadjuvant chemoradiotherapy on the change of PD-L1 expression in patients with locally advanced rectal adenocarcinoma.
    Richter I; Jirasek T; Dvorak J; Cermakova E; Rehakova P; Bartos J
    J BUON; 2017; 22(4):875-881. PubMed ID: 29155514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Value of diffusion-weighted MRI and apparent diffusion coefficient measurements for predicting the response of locally advanced rectal cancer to neoadjuvant chemoradiotherapy.
    Iannicelli E; Di Pietropaolo M; Pilozzi E; Osti MF; Valentino M; Masoni L; Ferri M
    Abdom Radiol (NY); 2016 Oct; 41(10):1906-17. PubMed ID: 27323759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The value of diffusion kurtosis magnetic resonance imaging for assessing treatment response of neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
    Yu J; Xu Q; Song JC; Li Y; Dai X; Huang DY; Zhang L; Li Y; Shi HB
    Eur Radiol; 2017 May; 27(5):1848-1857. PubMed ID: 27631106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complete Response Evaluation of Locally Advanced Rectal Cancer to Neoadjuvant Chemoradiotherapy Using Textural Features Obtained from T2 Weighted Imaging and ADC Maps.
    Azamat S; Karaman Ş; Azamat IF; Ertaş G; Kulle CB; Keskin M; Sakin RND; Bakır B; Oral EN; Kartal MG
    Curr Med Imaging; 2022; 18(10):1061-1069. PubMed ID: 35240976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive value of (18)FDG PET-CT for tumour response in patients with locally advanced rectal cancer treated by preoperative chemoradiotherapy.
    Kim JW; Kim HC; Park JW; Park SC; Sohn DK; Choi HS; Kim DY; Chang HJ; Baek JY; Kim SY; Kim SK; Oh JH
    Int J Colorectal Dis; 2013 Sep; 28(9):1217-24. PubMed ID: 23404344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer.
    Yu J; Li N; Wang X; Ren H; Wang W; Wang S; Song Y; Liu Y; Li Y; Zhou X; Luo A; Liu Z; Jin J
    Oncotarget; 2016 Sep; 7(39):64233-64243. PubMed ID: 27572313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.